Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

  1. Fleishaker, D.L.
  2. Garcia Meijide, J.A.
  3. Petrov, A.
  4. Kohen, M.D.
  5. Wang, X.
  6. Menon, S.
  7. Stock, T.C.
  8. Mebus, C.A.
  9. Goodrich, J.M.
  10. Mayer, H.B.
  11. Zeiher, B.G.
Revista:
Arthritis Research and Therapy

ISSN: 1478-6354,  1478-6362

Ano de publicación: 2012

Volume: 14

Número: 1

Tipo: Artigo

DOI: 10.1186/AR3685 GOOGLE SCHOLAR lock_openAcceso aberto editor

Obxectivos de Desenvolvemento Sustentable

Fonte de datos: Scopus